A newly developed long-term prediction model demonstrated greater accuracy in estimating prostate cancer–specific mortality compared with existing risk assessment tools. Unlike traditional ...

New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

I was fortunate to have my prostate cancer detected in 2017 before it was too late to treat and today, I'm cancer-free,' ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

The UCLA trial is currently enrolling patients.

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...